Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewGPi 688 is an allosteric glycogen phosphorylase inhibitor; acts at the indole site of glycogen phosphorylase. Inhibits glucagon-mediated hyperglycemia in vivo in the rat.
Sold with the permission of AstraZeneca UK Ltd.
分子量 | 419.88 |
公式 | C19H18ClN3O4S |
储存 | Store at +4°C |
纯度 | ≥99% (HPLC) |
CAS Number | 918902-32-6 |
PubChem ID | 10477191 |
InChI Key | UICNBXVDHCBKCE-PUODRLBUSA-N |
Smiles | OC[C@H](O)CN(C1=CC=CC=C1CC2NC(C3=CC4=C(SC(Cl)=C4)N3)=O)C2=O |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Freeman et al (2006) Sensitivity of glycogen phosphorylase isoforms to indole site inhibitors is markedly dependent on the activation state of the enzyme. Br.J.Pharmacol. 149 775 PMID: 17016495
Poucher et al (2007) An assessment of the in vivo efficacy of the glycogen phosphorylase inhibitor GPi688 in rat models of hyperglycaemia. Br.J.Pharmacol. 152 1239 PMID: 17934512
关键词: GPi 688, GPi 688 supplier, GPi688, glycogen, phosphorylase, inhibitors, hyperglycaemia, hyperglycemia, inhibits, astrazeneca, Phosphorylases, 3967, Tocris Bioscience
目前没有该产品的评论。 Be the first to review GPi 688 and earn rewards!
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image